Evaluating the long-term safety of TPN171H tablet for erectile dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label study aims to assess the long-term safety and efficacy of the TPN171H tablet in men suffering from erectile dysfunction (ED). Participants will be men aged 18 to 75 who have experienced ED for at least three months and meet specific criteria regarding their sexual performance. The study will monitor the participants' responses to the treatment over an extended period to determine its effectiveness and safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years to 75 years (inclusive);
* Males with ED at least 3 months;
* IIEF-5 ≤ 21 at visit 1;
* Patients in a stable, heterosexual relationship during the study;
* At the end of the untreated baseline period, the following conditions are met：（1）The subject must make at least four attempts at sexual intercourse during the untreated baseline period. （2）At least 50% of attempts during this period must be unsuccessful,（unsuccess means at least one of the first three questions should be answered "No" in SEP）.（3）5≤IIEF-EF≤25.
* Patients who are willing to have 4 or more attempts of sexual intercourse per month, demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial;
* Patients who are willing to take proper contraceptive during the study and within 3 months after the last dose;
* Patients who have voluntarily decided to participate in this study, and signed the informed consent form.

Exclusion Criteria:

* Patients who have a history of hypersensitivity to other PDE5 inhibitors or TPN171H;
* Patients with anatomical malformations of the penis;
* Patients with primary hypoactive sexual desire;
* Patients with ED, which is caused by any other primary sexual disorder;
* Patients with ED, which is caused by spinal injury or have had a radical prostatectomy or other surgery;
* Patients who have a penile implant;
* Patients who do not respond to marketed PDE5 inhibitors or have adverse reactions that lead to drug discontinuation;
* CYP3A4 potent inhibitors, moderate inhibitors, and potent inducers need to be used during the trial or discontinued for less than 31 days before enrollment;
* Subjects who are taking nitrate or NO donor drugs, guanylate cyclase agonists and cannot be discontinued during the trial;
* Patients with the following cardiovascular disease: Myocardial infarction or stroke within the last 6 months; Unstable angina or angina occurring during sexual intercourse; New York Heart Association Class 2 or greater heart failure in the last 6 months;
* Uncontrolled hypotension (\<90/60mmHg) or uncontrolled hypertension (≥180/110mmHg);
* Patients with diabetic complications (diabetic nephropathy, peripheral neuropathy);
* Patients with hepatic or renal dysfunction as per the following: AST, ALT\>3\*ULN, serum creatinine exceeds 50% of the upper limit of normal value;
* Patients with active gastrointestinal ulcers and bleeding disorders;
* Patients who have a history of NAION, or with a known genetically degenerative retinopathy, including retinitis pigmentosa;
* Patients who have a history of sudden decrease or loss of hearing;
* Patients with a history of severe central nervous system injury or peripheral muscular neurological disease in the past 6 months;
* Patient with a history of malignancy;
* Patients with significant neurological abnormalities who are unable or unwilling to cooperate;
* Patients whose partner is breastfeeding/pregnant/trying to become pregnant, has a gynecological disease or is restricted in their activities during treatment;
* Patients who have used other drugs in clinical trials within the last 1 month;
* For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate.

Where it's running

• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• Peking University Third Hospital
  Beijing, Beijing, China Recruiting
• Guangzhou First People's Hospital
  Guangzhou, Guangdong, China Recruiting
• The Fifth Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting
• The Third Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting
• Shantou Central Hospital
  Shantou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Hui Jiang — Peking University First Hospital
• Study coordinator: Huaqing Duan
• Email: huaqing.duan@vigonvita.cn
• Phone: +86-18061926005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HIP2602 for Erectile Dysfunction: Testing a new treatment in adults

  This study tests whether HIP2602, alone or with related formulations, can improve erectile function in adult men with long-standing erectile dysfunction who partner with the same adult female partner.

  Recruiting Phase 3 Hanmi Pharmaceutical Company Limited · Busan · NCT07899073

• Platelet-Rich Plasma for Erectile Dysfunction After Prostate Surgery

  This trial tests whether injecting a patient’s own platelet-rich plasma can improve erectile function in men who have persistent ED more than a year after nerve-sparing radical prostatectomy.

  Recruiting Herlev and Gentofte Hospital · Herlev · NCT07863388

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• Piezoelectric Low-Intensity Shockwave Therapy for erectile dysfunction in PDE5i nonresponders

  This study tests whether four weeks of low‑intensity, linear piezoelectric shockwave therapy can improve erectile function in men with ED who did not respond to PDE5 inhibitors.

  Recruiting The University of Hong Kong · Hong Kong · NCT07820748

• Sexual function and quality of life in monogamous vs polygamous marriages among Egyptian men

  This is a web-based survey to see if marital structure affects erectile function and sexual quality of life in Egyptian men who are married.

  Recruiting Al-Azhar University · Cairo · NCT07783958

• Lifestyle changes to improve erectile function in men with metabolic syndrome

  A six-month lifestyle program is being tried to see if it improves erectile function and penile blood flow in men who have erectile dysfunction linked to metabolic syndrome.

  Recruiting at 2 sites Al-Azhar University · Cairo and 1 other locations · NCT07758842

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.